Global Microbial API Market Size study, by Host (Mammalian, Bacterial, Fungal), by Type (Antibody, Peptide, Protein, Small Molecule, Vaccine), by Site (In-house, Outsourced), by End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) and

Global Microbial API Market Size study, by Host (Mammalian, Bacterial, Fungal), by Type (Antibody, Peptide, Protein, Small Molecule, Vaccine), by Site (In-house, Outsourced), by End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) and Regional Forecasts 2022-2032

Global Microbial API Market is valued approximately at USD 60.3 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.91% over the forecast period 2024-2032. Microbial API (Active Pharmaceutical Ingredient) refers to compounds produced by microorganisms, such as bacteria, fungi, or yeast, that have therapeutic effects and are used as active ingredients in pharmaceuticals. These APIs are derived through fermentation processes, where microorganisms are cultivated to produce substances with medicinal properties. Examples include antibiotics like penicillin, which is produced by the mold Penicillium chrysogenum, and other biologically active molecules like statins and immunosuppressants. Microbial APIs (Active Pharmaceutical Ingredients) play a crucial role in the pharmaceutical industry, providing the essential components for manufacturing medications that address a wide range of diseases. The increasing prevalence of chronic illnesses such as Alzheimer's disease and cardiovascular conditions drives the demand for microbial APIs, as these ingredients are vital in developing effective treatments. The pharmaceutical industry's ongoing efforts to find new therapies for chronic diseases underscore the growing importance of microbial APIs in creating essential medications.

The Global Microbial API Market is experiencing significant growth, propelled by several key factors. The rise in chronic diseases worldwide has led to a sustained demand for APIs containing microorganisms. As the pharmaceutical industry faces the challenges of an expanding list of chronic conditions, including heart disease and neurological disorders, the need for innovative treatments becomes imperative. The World Health Organization (WHO) reports that non-communicable diseases account for 71% of global deaths, with cardiovascular diseases alone causing over 18 million deaths in 2021. This highlights the critical role of microbial APIs in developing life-saving medications. Furthermore, the increasing demand for biosimilar and generic medications, driven by the need to reduce healthcare costs, contributes to the market's expansion. The Association for Accessible Medicines reported significant savings to the U.S. healthcare system from generic and biosimilar medications, emphasizing the economic benefits of microbial APIs in drug production.

The key region in the Global Microbial API Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America dominates the market in terms of revenue, supported by well-developed healthcare infrastructures, high healthcare spending, and the presence of major pharmaceutical companies' manufacturing and R&D facilities. Europe holds the second-largest market share, driven by rising healthcare costs, increased R&D spending, and a growing generics market. The Asia-Pacific region is expected to witness the fastest growth, fueled by the rapidly expanding pharmaceutical industry in China and India, foreign investments in production facilities, and government initiatives to support domestic manufacturing.



Major market players included in this report are:

Merck & Co., Inc.

DSM

CSPC Pharmaceutical Group Limited

KOLON LIFE SCIENCE

Topfond Pharmaceutical Co., Ltd.

Shandong Lukang Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

Lonza

Pfizer Inc.

Novartis AG

Sanofi

Johnson & Johnson

GlaxoSmithKline plc



The detailed segments and sub-segment of the market are explained below:

By Host:

Mammalian

Bacterial

Fungal



By Type:

Antibody

Peptide

Protein

Small Molecule

Vaccine



By Site:

In-house

Outsourced



By End User:

Pharmaceutical Companies

Biopharmaceutical Companies

Others



By Region:

North America

U.S.

Canada



Europe

UK

Germany

France

Spain

Italy

ROE



Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC



Latin America

Brazil

Mexico

Rest of Latin America



Middle East & Africa

Saudi Arabia

South Africa

RoMEA



Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032



Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.